Rh-endostatin combined with docetaxel, platinates and fluoropyrimidines as first-line chemotherapy for ad-vanced gastric cancer

DU Chunxia; CHEN Shanshan; LIU Xiaoyan; ZHANG Honggang

Abstract：Objective To investigate the efficacy and safety of rh-endostatin ( endostar) combined with docetaxel, platinates and fluoropyrimidines as first-line chemotherapy for advanced gastric cancer. Methods Twenty-five patients with advanced gastric cancer were enrolled into this study from Jan. 2011 to Jun. 2013. Seventeen patients received docetaxel, oxalipatin and flourouracil ( DOF) regimen:docetaxel 40mg/m2 iv, d1;oxaliplatin 85mg/m2 iv,d2;flourouracil 400mg/m2 iv, 600mg/m2 continuous iv 22h d2-d3 , with 2 weeks as a cycle. Eight patients received docetaxel, cisplatin and capecitabine ( DCX) regimen:docetaxel 40mg/m2 iv, d1;cisplatin 25mg/m2 iv, d2-d3;capetitabine 1000mg/m2 bid po, d1-d8 , with 2 weeks as a cycle. Endostar was administered 15mg/d iv, d1-d10 . The response rate was evaluated according to RECIST1. 1 criteria, and the toxicities were evaluated according to NCI CTC 3. 0 standard.Progression-free survival (PFS) and overall survival (OS) were also observed. Results Among the 24 evaluable cases, PR was observed in 10 patients, SD in 6 patients, and PD in 8 patients. The response rate was 41. 7%, and the disease control rate was 66. 7%. Digestive reaction and myelosuppression were the most common toxicities. Neutropenia( 6 cases) was the most frequent grade 3-4 toxicity. One patient experienced cardiac toxicity. The median follow-up was 14. 6 months, the median PFS was 8. 0 months, and the median OS was 11. 0 months. Conclusion Endostar combined with docetaxel, platinates and fluoropyrimidines is an effective and safe regimen as first-line chemotherapy for advanced gastric cancer. It is worthy of further large scale clinical trial.